Today's Veterinary Practice provides comprehensive information to keep every small animal practitioner up to date on companion animal medicine and surgery as well as practice building and management.
Issue link: http://todaysveterinarypractice.epubxp.com/i/619503
Today's VeTerinary news tvpjournal.com | January/February 2016 TOEGRIPS NOW AVAILABLE FOR PREVENTING INJURY Many homeowners love hardwood and tile foors, but according to veterinarian Dr. Julie Buzby, dogs weren't designed to live on this fooring. Slipping impacts dogs' joints and increases the risk of injury, and it can be an emotionally traumatic experience as well. Therefore, Dr. Buzby has developed Dr. Buzby's ToeGrips for Dogs, which she describes as "a biomechanics solution to a biomechanics problem." ToeGrips are nonslip nail grips that slide onto dogs' nails, adhere by friction, and provide traction and confdence for senior, arthritic, and special needs dogs. ToeGrips come in 7 sizes and are distributed by more than 1000 veterinary professionals in 20 countries, through MWI Veterinary Supply (mwivet.com), and directly at toegrips.com. VETPREP CREATORS LAUNCH VIRALVET MOBILE APP The creators of VetPrep announced the release of a new mobile app. ViralVet enables veterinary professionals to share challenging cases instantly with a global community. The free app features a live, customizable feed that users can browse by species and specialties and is searchable by tags or keywords. Users can post their own photos to share discoveries or solicit professional opinions on cases that are interesting, novel, challenging, or didactic. ViralVet is available at no cost for iPhone and Android in North America, the United Kingdom, Australia, New Zealand, and select Caribbean and European countries. For more information, visit viralvet.com. The Latest news in Veterinary Medicine INTERNATIONAL TASK FORCE TO SIMPLIFY TOPIC OF EPILEPSY IN DOGS & CATS University of Minnesota College of Veterinary Medicine faculty member Ned Patterson, DVM, is participating in the International Veterinary Epilepsy Task Force, created to streamline the process and create a common language for researching, diagnosing, and treating epilepsy in dogs and cats. Dr. Patterson has focused his research on understanding and treating epilepsy in dogs as a model for human epilepsy using novel drugs and novel devices. The task force is a 26-member collaboration that includes veterinary practitioners and neuropathology and neurology experts from around the world. For more information, visit biomedcentral.com/1746-6148/11/148. Caution Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Indications SENTINEL ® SPECTRUM ® (milbemycin oxime/lufenuron/praziquantel) is indicated for the prevention of heartworm disease caused by Diroflaria immitis; for the prevention and control of fea populations (Ctenocephalides felis); and for the treatment and control of adult roundworm (Toxocara canis, Toxascaris leonina), adult hookworm (Ancylostoma caninum), adult whipworm (Trichuris vulpis), and adult tapeworm (Taenia pisiformis, Echinococcus multilocularis and Echinococcus granulosus) infections in dogs and puppies two pounds of body weight or greater and six weeks of age and older. Dosage and Administration SENTINEL SPECTRUM should be administered orally, once every month, at the minimum dosage of 0.23 mg/lb (0.5 mg/kg) milbemycin oxime, 4.55 mg/lb (10 mg/kg) lufenuron, and 2.28 mg/lb (5 mg/kg) praziquantel. For heartworm prevention, give once monthly for at least 6 months after exposure to mosquitoes. Dosage Schedule Body Weight Milbemycin Oxime per chewable Lufenuron per chewable Praziquantel per chewable Number of chewables 2 to 8 lbs. 2.3 mg 46 mg 22.8 mg One 8.1 to 25 lbs. 5.75 mg 115 mg 57 mg One 25.1 to 50 lbs. 11.5 mg 230 mg 114 mg One 50.1 to 100 lbs. 23.0 mg 460 mg 228 mg One Over 100 lbs. Administer the appropriate combination of chewables To ensure adequate absorption, always administer SENTINEL SPECTRUM to dogs immediately after or in conjunction with a normal meal. SENTINEL SPECTRUM may be offered to the dog by hand or added to a small amount of dog food. The chewables should be administered in a manner that encourages the dog to chew, rather than to swallow without chewing. Chewables may be broken into pieces and fed to dogs that normally swallow treats whole. Care should be taken that the dog consumes the complete dose, and treated animals should be observed a few minutes after administration to ensure that no part of the dose is lost or rejected. If it is suspected that any of the dose has been lost, redosing is recommended. Contraindications There are no known contraindications to the use of SENTINEL SPECTRUM. Warnings Not for use in humans. Keep this and all drugs out of the reach of children. Precautions Treatment with fewer than 6 monthly doses after the last exposure to mosquitoes may not provide complete heartworm prevention. Prior to administration of SENTINEL SPECTRUM, dogs should be tested for existing heartworm infections. At the discretion of the veterinarian, infected dogs should be treated to remove adult heartworms. SENTINEL SPECTRUM is not effective against adult D. immitis. Mild, transient hypersensitivity reactions, such as labored breathing, vomiting, hypersalivation, and lethargy, have been noted in some dogs treated with milbemycin oxime carrying a high number of circulating microflariae. These reactions are presumably caused by release of protein from dead or dying microflariae. Do not use in puppies less than six weeks of age. Do not use in dogs or puppies less than two pounds of body weight. The safety of SENTINEL SPECTRUM has not been evaluated in dogs used for breeding or in lactating females. Studies have been performed with milbemycin oxime and lufenuron alone. Adverse Reactions The following adverse reactions have been reported in dogs after administration of milbemycin oxime, lufenuron, or praziquantel: vomiting, depression/lethargy, pruritus, urticaria, diarrhea, anorexia, skin congestion, ataxia, convulsions, salivation, and weakness. To report suspected adverse drug events, contact Virbac at 1-800-338-3659 or the FDA at 1-888-FDA-VETS. Information for Owner or Person Treating Animal Echinococcus multilocularis and Echinococcus granulosus are tapeworms found in wild canids and domestic dogs. E. multilocularis and E. granulosus can infect humans and cause serious disease (alveolar hydatid disease and hydatid disease, respectively). Owners of dogs living in areas where E. multilocularis or E. granulosus are endemic should be instructed on how to minimize their risk of exposure to these parasites, as well as their dog's risk of exposure. Although SENTINEL SPECTRUM was 100% effective in laboratory studies in dogs against E. multilocularis and E. granulosus, no studies have been conducted to show that the use of this product will decrease the incidence of alveolar hydatid disease or hydatid disease in humans. Because the prepatent period for E. multilocularis may be as short as 26 days, dogs treated at the labeled monthly intervals may become reinfected and shed eggs between treatments. Manufactured for: Virbac AH, Inc. P.O. Box 162059, Ft. Worth, TX 76161 NADA #141-333, Approved by FDA © 2015 Virbac Corporation. All Rights Reserved. SENTINEL and SPECTRUM are registered trademarks of Virbac Corporation. 02/15 14